Search alternatives:
wt decrease » _ decrease (Expand Search), nn decrease (Expand Search), awd decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
e mean » _ mean (Expand Search), a mean (Expand Search), i mean (Expand Search)
Showing 741 - 760 results of 108,229 for search '(( e mean decrease ) OR ( 5 ((((wt decrease) OR (we decrease))) OR (a decrease)) ))', query time: 1.93s Refine Results
  1. 741
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  2. 742
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  3. 743
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  4. 744
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  5. 745
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  6. 746
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  7. 747
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  8. 748
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  9. 749
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  10. 750
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  11. 751
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  12. 752
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  13. 753
    eNOS phosphorylation increased intracellular ROS generation and decreased cell viability in BH4-depleted cells.

    eNOS phosphorylation increased intracellular ROS generation and decreased cell viability in BH4-depleted cells. by Hu Peng (396074)

    Published 2015
    “…<p>(A) HEK 293 cells were treated with DMSO or 10mM DAHP for 24 hours to deplete BH4, then transfected with either control vector or WT eNOS plasmid DNA overnight. …”
    Save to List
    Saved in:
  14. 754
    <i>Vps13</i> mutant flies show a decreased life span, age dependent impairment of locomotor function and neurodegeneration.

    <i>Vps13</i> mutant flies show a decreased life span, age dependent impairment of locomotor function and neurodegeneration. by Jan J. Vonk (3686662)

    Published 2017
    Save to List
    Saved in:
  15. 755
    Lithium Decreases Glial Fibrillary Acidic Protein in a Mouse Model of Alexander Disease

    Lithium Decreases Glial Fibrillary Acidic Protein in a Mouse Model of Alexander Disease by Christine M. LaPash Daniels (796881)

    Published 2015
    “…Here we tested whether lithium treatment would decrease levels of GFAP in a mouse model of Alexander disease. …”
    Save to List
    Saved in:
  16. 756
    Effects of A1AR expression on response to hypoxia at E9.5 and E12.5.

    Effects of A1AR expression on response to hypoxia at E9.5 and E12.5. by Daniela L. Buscariollo (140729)

    Published 2013
    “…In hypoxia, E9.5 A1AR +/− heart rates decreased then returned to baseline levels following recovery in room air (p<0.0001 and p<0.01, for t = 25 and t = 40 compared to t = 0, respectively). …”
    Save to List
    Saved in:
  17. 757
    TachypleginA treatment causes a decrease in the motor activity of the TgMyoA motor complex.

    TachypleginA treatment causes a decrease in the motor activity of the TgMyoA motor complex. by Aoife T. Heaslip (207534)

    Published 2010
    Save to List
    Saved in:
  18. 758
    <i>Syx5</i> suppression in human cells decreases copper accumulation but does not affect rate of turnover.

    <i>Syx5</i> suppression in human cells decreases copper accumulation but does not affect rate of turnover. by Melanie Norgate (234832)

    Published 2010
    Save to List
    Saved in:
  19. 759
    HA-MAD1 tumors have increased CIN and decreased p53.

    HA-MAD1 tumors have increased CIN and decreased p53. by Sarah E. Copeland (13951506)

    Published 2024
    Save to List
    Saved in:
  20. 760
    Retnla overexpression decreased the levels of IL-4, IL-5, and IL-13 in OVA-induced asthmatic lung.

    Retnla overexpression decreased the levels of IL-4, IL-5, and IL-13 in OVA-induced asthmatic lung. by Mi-Ran Lee (664596)

    Published 2014
    Save to List
    Saved in:

Search Tools: